Q3 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Continuing operations | Full year guidance Core Net Expenses expected to be around 0.5bn. Financial Result Expected to be in the 15-16% range Core Tax Rate References Structurally lower tax rate vs. Novartis incl. Sandoz due to different geographic mix Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. 41 Investor Relations | Q3 2023 Results Abbreviations FINANCIAL PROFILE NOVARTIS | Reimagining Medicine

View entire presentation